Genmab A (GMAB) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access GMAB Annual Income Statement →
The income statement data below highlights shifts in Genmab A's operating performance over recent quarters.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
Q4 2025
0 0 0 (Jun 30 2024)
Revenues
Total Revenue3,720.00
Costs & Expenses
Cost of Goods and Services Sold238.00
Gross Profit3,482.00
Selling, Administration, Marketing626.00
Research and Development Expense1,606.00
Other Operating Expense / -Income185.00
Total operating costs including COS2,655.00
Operating income / -loss1,065.00
Net Interest Expense / -Income0.00
Other loss / -income-139.00
Total costs & expenses2,516.00
Income & Taxes
Income / -loss before income taxes1,204.00
Income taxes expenses / -benefit241.00
Income after income taxes963.00
Income / -loss from continuing operations963.00
Net income / -loss963.00
Income / -loss to shareholder963.00
EBIT1,204.00
EBITD1,212.58
EBITDA1,215.07
Earnings Per Share
Basic EPS (excl. extra items)0.00
Basic Net EPS0.00
Basic shares outstanding (Mill. of Units)0.00
Diluted Net EPS0.00
Diluted average shares (Mill. of Units)0.00
4 historic quarters locked

Sign in to unlock the full Genmab A income statement history.

About GMAB Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.